Needs with Regard to Decision Support Systems for Treating Patients with Incurable Non-small Cell Lung Cancer
暂无分享,去创建一个
J. J. Tamminga | E. Steyerberg | H. D. de Vet | B. Onwuteaka-Philipsen | F. Schramel | D. Révész | E. M. van de Garde | V. Coupé | E. Engelhardt
[1] D. Révész,et al. Decision support systems for incurable non-small cell lung cancer: a systematic review , 2017, BMC Medical Informatics and Decision Making.
[2] P. Lambin,et al. Decision support systems for personalized and participative radiation oncology☆ , 2017, Advanced drug delivery reviews.
[3] W. Tam,et al. Novel therapeutic targets on the horizon for lung cancer. , 2016, The Lancet. Oncology.
[4] Y. Boumber,et al. Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC , 2016, Front. Oncol..
[5] Daniel L. Rubin,et al. Toward rapid learning in cancer treatment selection: An analytical engine for practice-based clinical data , 2016, J. Biomed. Informatics.
[6] D. Costa,et al. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches , 2016, Therapeutic advances in respiratory disease.
[7] D. Ettinger,et al. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.
[8] Funda Meric-Bernstam,et al. The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform. , 2015, Drug discovery today.
[9] Paul K J Han,et al. Physicians' perceptions of the value of prognostic models: the benefits and risks of prognostic confidence , 2015, Health expectations : an international journal of public participation in health care and health policy.
[10] N. Zhang,et al. Incorporation of life expectancy estimates in the treatment of palliative care patients receiving radiotherapy: treatment approaches in light of incomplete prognostic models. , 2015, Annals of palliative medicine.
[11] R. Gentzler,et al. Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC). , 2015, Translational lung cancer research.
[12] Adam P Dicker,et al. American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Lei Han,et al. Predictive value of K-ras and PIK3CA in non-small cell lung cancer patients treated with EGFR-TKIs: a systemic review and meta-analysis , 2015, Cancer biology & medicine.
[14] P. Hammerman,et al. Squamous Cell Lung Cancer: From Tumor Genomics to Cancer Therapeutics , 2015, Clinical Cancer Research.
[15] E. Smets,et al. Breast cancer specialists' views on and use of risk prediction models in clinical practice: A mixed methods approach , 2014, Acta oncologica.
[16] E. Chow,et al. How radiation oncologists evaluate and incorporate life expectancy estimates into the treatment of palliative cancer patients: a survey-based study. , 2013, International journal of radiation oncology, biology, physics.
[17] Jae Park,et al. How do medical doctors use a web-based oncology protocol system? A comparison of Australian doctors at different levels of medical training using logfile analysis and an online survey , 2013, BMC Medical Informatics and Decision Making.
[18] D De Ruysscher,et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] J. Schiller,et al. Prognostic Models to Predict Survival in Non–Small-Cell Lung Cancer Patients Treated with First-Line Paclitaxel and Carboplatin with or without Bevacizumab , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[20] Jerome A. Osheroff,et al. Bmc Medical Informatics and Decision Making Information Management to Enable Personalized Medicine: Stakeholder Roles in Building Clinical Decision Support , 2009 .
[21] L. Seymour,et al. A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[22] S. Ramalingam,et al. Molecularly-targeted therapies for non-small cell lung cancer , 2005, Expert opinion on pharmacotherapy.
[23] S. Rodenhuis,et al. The molecular genetics of human lung cancer. , 1989, The European respiratory journal.
[24] J. Gainor,et al. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. , 2017, The oncologist.
[25] C. Rudin,et al. Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.